Roche Holding AG’s gene therapy Elevidys failed to get the backing of European regulators.
The European Medicines Agency’s drug advisory committee recommended against Elevidys for children with Duchenne muscular dystrophy, the agency said Friday. The medicine had been intended for children aged 3 to 7 years who are able to walk.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.